GlaxoSmithKline Pharmaceuticals Limited has formally notified stock exchanges about an upcoming board meeting scheduled for May 13, 2026. The pharmaceutical company issued the intimation on April 22, 2026, in compliance with regulatory requirements under the Listing Obligations and Disclosure Requirements Regulations, 2015.

Board Meeting Details

The meeting agenda encompasses several critical corporate matters that require board approval and consideration.

Key Agenda Items

The board will deliberate on multiple significant matters during the scheduled session:

• Financial Results Approval: Review and approval of audited financial results for both standalone and consolidated statements
• Quarterly and Annual Performance: Assessment of financial performance for the quarter and full year ended March 31, 2026
• Dividend Consideration: Evaluation and potential recommendation of dividend distribution to equity shareholders

Regulatory Compliance

The notification demonstrates GlaxoSmithKline Pharmaceuticals' adherence to mandatory disclosure requirements. The company has fulfilled its obligation under Regulations 29 and 33 of the LODR 2015, which mandate timely intimation to stock exchanges regarding board meetings that will consider financial results.

The formal communication was addressed to both BSE Limited and The National Stock Exchange of India Limited, ensuring comprehensive market notification. Company Secretary Ajay Nadkarni signed the official intimation, maintaining proper corporate governance protocols.

Corporate Information

GlaxoSmithKline Pharmaceuticals Limited operates from its corporate headquarters at GSK House, Dr. Annie Besant Road, Worli, Mumbai. The company maintains its corporate identity number as L24239MH1924PLC001151, reflecting its long-standing presence in the Indian pharmaceutical sector since 1924.

GlaxoSmithKline Pharmaceuticals Limited has announced a key leadership appointment, naming Mr. Vinay Subramanian as Commercial Head – Oncology to its leadership team. The appointment, effective 20th April 2026, was disclosed to stock exchanges in compliance with Regulation 30 of SEBI Listing Regulations.

Leadership Appointment Details

The company informed BSE Limited and National Stock Exchange of India Limited about the appointment through an official communication dated 21st April 2026. Subramanian will be based out of Mumbai and will be part of the senior management personnel of the company.

Professional Background and Experience

Vinay Subramanian brings extensive experience spanning over 24 years in the pharmaceuticals, life science, healthcare devices, and medical technology sectors. His appointment strengthens GSK's oncology division leadership with proven industry expertise.

Prior to joining GSK, Subramanian served as the India Enabling leader - Enterprise & Neighboring Countries at Roche Products India Pvt Ltd. In this role, he was responsible for managing the immunotherapy portfolio and was an integral part of their leadership team.

Previous Leadership Roles

Subramanian's career includes significant leadership positions across major healthcare organizations:

Educational Qualifications

Subramanian holds comprehensive educational credentials that complement his extensive industry experience:

Regulatory Compliance

The appointment disclosure was made in accordance with Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company confirmed that there are no relationships between directors that require disclosure under the regulatory framework.

The communication was signed by Ajay Nadkarni, Vice President – Administration, Real Estate & Company Secretary, ensuring proper corporate governance protocols were followed in the announcement.